Index, author, year, reference
| Patients (n) | CLD | Markers in panel | AUROC (T-V)† |
- † The area under the receiver operating characteristic curves (AUROC) for the diagnosis of significant fibrosis (stage 2–4 by the METAVIR or Scheuer classification, 3–6 by the Ishak score). T-V, AUROC values of training group and validation group.
- ‡ ‡Differentiation cirrhosis from no cirrhosis.
- § Differentiation advanced fibrosis (Ishak 4–6) from mild to moderate fibrosis (Ishak 0–3).
- ¶ Differentiation advanced hepatic fibrosis (defined as F3–F4 by METAVIR) from milder (F0–F2).
A2M, α2-macroglobulin; AAR, AST/ALT ratio; ALP, alkaline phosphatase; ALT, alanine aminotransferase; apoA1, apolipoprotein A1; APRI, aspartate aminotransferase to platelet ration index; AST, aspartate aminotransferase; AUROC, area under the receiver operating characteristic curves; BMI, body mass index; CLD, chronic liver disease; GGT, γ-glutamyltransferase; HA, hyaluronic acid; HBV, hepatitis B virus; HCV, hepatitis C virus; NAFLD, Nonalcoholic fatty liver disease; HIV, human immunodeficiency virus; HOMA-IR, homeostasis model assessment insulin resistance (fast glucose × plasma gluc/22.5); Hpt, haptoglobin; INR, international normalized ratio; IV-7S, type IV collagen 7s domain; MMP-1, metalloproteinase 1; Mn-SOD, manganese superoxide dismutase; PCHE, pseudocholinesterase; PI, prothrombin index; PIIINP, N-terminal peptide of type β pro-collagen; PLT, platelet count; PT, prothrombin time; TB, total bilirubin; TC, total cholesterol; TG, triglycerides; TIMP-1, tissue inhibitor of metalloproteinase 1; β-NAG, N-acetyl β-glucosaminidase.
|
AAR, Williams, 1988 | 177 | Mixed | AAR | n/a |
PGA index, Poynard, 1991 | 624 | Alcohol | PT, GGT, apoA1 | n/a |
PGAA index, Naveau, 1994 | 525 | Alcohol | PT, GGT, apoA1, A2M | n/a |
CDS index, Bonacini, 1997 | 75 | HCV | PLT, AAR, PT | n/a |
AP index, Poynard 1997 | 620 | HCV | Age, PLT | 0.763–0.690 |
BAAT score, Ratziu 2000 | 93 | NAFLD | Age, BMI, ALT, TG | 0.84 |
Fortunato, 2001 | 103 | HCV | Fibronectin, prothrombin, ALT, PCHE, Mn-SOD, β-NAG | n/a |
Pohl, 2001 | 211 | HCV | AAR, PLT | n/a |
FibroTest, Imbert-Bismut, 200111 | 339 | HCV | A2M, Hpt, GGT, ApoA1, bilirubin | 0.836–0.870 |
Kaul, 200212 | 264 | HCV | PLT, AST, sex, spider nevi | n/a |
Forns index, Forns, 200213 | 476 | HCV | Age, GGT, cholesterol, PLT | 0.86–0.81 |
APRI, Wai, 200314 | 270 | HCV | AST, PLT | 0.80–0.88 |
ELF-score, Rosenberg, 200415 | 1021 | Mixed | Age, HA, PIIINP, TIMP-1 | 0.804 |
FIBROSpect II, Patel, 200416 | 696 | HCV | HA, TIMP-1, A2M | 0.831–0.823 |
FPI, Sud, 200417 | 302 | HCV | Age, AST, TC, HOMA-IR, past alcohol intake | 0.84–0.77 |
MP3, Leroy, 200418 | 194 | HCV | PIIINP, MMP-1 | 0.82 |
HALT-C, Lok, 200519 | 1141 | HCV | PLT, AAR, INR | 0.78–0.81‡ |
Hepascore, Adams, 200520 | 221 | HCV | Bilirubin, GGT, HA, A2M, age, sex | 0.85–0.82 |
Fibrometer, Cales, 200521 | 383 | Mixed | PLT, PI, AST, A2M, HA, urea, age | 0.883–0.892 |
SHASTA index, Kelleher, 200522 | 95 | HCV/HIV | HA,AST and albumin | 0.878 |
Sakugawa, 200523 | 112 | NAFLD | IV-7S, HA | n/a |
Hui, 200524 | 235 | HBV | BMI, PLT, albumin, TB, ALP | 0.803–0.765 |
SLFG, Zeng, 200525 | 372 | HBV | A2M, age, GGT, HA | 0.84–0.77 |
FIB-4, Sterling, 200626 | 832 | HCV/HIV | Age, AST, ALT, PLT | 0.765§ |
Virahep-C, Fontana, 200627 | 399 | HCV | age, AST, ALP, PLT | 0.837–0.851 |
Mohamadnejad, 200628 | 276 | HBV | HBV DNA levels, ALP, albumin, PLT, | 0.91–0.85 |
FibroIndex, Koda, 200729 | 402 | HCV | PLT, AST, γ-globulin | 0.828–0.835 |
Alsatie, 200730 | 286 | HCV | diabetes mellitus, PLT, AST, INR, bilirubin | 0.79–0.75¶ |
Esmat, 200731 | 220 | HCV | HA, age | 0.84§ |
NAFLD fibrosis score, Angulo, 200732 | 733 | NAFLD | Age, BMI, PLT, albumin, AAR, hyperglycemia | 0.88–0.82 |